Viking Therapeutics with strong analyst confidence – price target well above current price
This article was created with the help of artificial intelligence.
Key Takeaways
- Viking Therapeutics (VKTX) closed at $42.13 on July 7, 2026, an increase of 8.83% compared to the previous day.
- 23 of 24 analysts recommend the stock for purchase (22 Buy, 1 Strong Buy), no analyst recommends selling (as of July 7, 2026).
- The average price target is $93.60, with a range from $83.00 to $101.00 – representing upside potential of approximately 122%.
- The RSI stood at 68.02 points on July 6, 2026, after repeatedly rising above 70 in late June.
- VK2809, the leading pipeline candidate, is undergoing Phase IIb studies for the treatment of NASH and NAFLD.
Viking Therapeutics Inc. (VKTX) closed at $42.13 on July 7, 2026, marking an increase of 8.83 percent compared to the previous day ($38.71). The biotech company focused on metabolic and endocrine disorders is at the center of positive analyst ratings, signaling significant upside potential.
Broad analyst consensus supports positive assessment
Of a total of 24 analysts covering Viking Therapeutics, 22 recommend the stock for purchase, while one analyst issues a Strong Buy recommendation (as of July 7, 2026). Only one analyst recommends holding the position – sell recommendations are entirely absent. This distribution underscores high confidence in the company's prospects.
The average analyst price target is $93.60, with a median of $95.00. The range spans from a conservative target of $83.00 to an optimistic scenario of $101.00. Based on the current price, this represents an upside potential of approximately 122 percent to the mean.
Technical indicators point to consolidation
The Relative Strength Index (RSI) stood at 68.02 points on July 6, 2026. An RSI above 70 is typically considered overbought, while a value below 30 is considered oversold. Viking Therapeutics is thus moving in the upper neutral range, following a period when the RSI repeatedly surpassed the 70-point mark in late June – on June 24, it reached 75.03, and on June 29, even 75.36.
Trading volume on July 7, 2026, amounted to just 2,997 shares traded – a significantly below-average figure indicating low market activity. The intraday range was between $38.68 (low) and $42.79 (high).
Pipeline with advanced development candidates
As a clinical biotech company, Viking Therapeutics operates several development programs. The leading candidate VK2809 is an orally administered, tissue- and receptor-selective agonist of the thyroid hormone receptor beta (TRβ). The molecule is undergoing Phase IIb studies for the treatment of non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients as well as non-alcoholic fatty liver disease (NAFLD).
Additional compounds in the pipeline include VK5211, an oral, non-steroidal selective androgen receptor modulator in Phase II studies for patients following hip fracture surgery, as well as VK0612, an oral candidate for type 2 diabetes that is approaching Phase IIb studies.
Market position in a competitive segment
The company operates in the highly competitive field of metabolic disorders, where several major pharmaceutical companies and specialized biotechs are active. Treatment of NASH and NAFLD is considered a medical need with high commercial potential, as effective therapies are currently lacking. Market development depends significantly on clinical trial results and regulatory approvals.
Viking Therapeutics has experienced a phase of technical strength in recent weeks, reflected in the RSI values. The current consolidation around $42 could represent a pause after previous price gains. Investors are particularly monitoring progress in ongoing clinical programs, as these determine the company's long-term value.